Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), and amendments thereto, ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts more than Nifty Microcap 250 and 1.3 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Eiko Lifesciences' Board approved unaudited standalone and consolidated results for Q2 and H1 FY26 ended 30 September 2025, with a clean (unmodified) limited review from auditor PSV Jain & Associates. On a consolidated basis, revenue from operations jumped to ₹1,167.17 lakhs in Q2 (~43% YoY from ₹815.51 lakhs) and H1 revenue grew ~18% to ₹2,238.32 lakhs; consolidated profit attributable to shareholders surged to ₹107.56 lakhs in Q2 (vs ₹28.15 lakhs YoY) and H1 PAT jumped to ₹198.98 lakhs from ₹65.29 lakhs. On a standalone basis, however, H1 revenue from operations actually fell ~10% YoY to ₹1,664.97 lakhs (from ₹1,848.95 lakhs), even as standalone PAT rose sharply to ₹150.98 lakhs from ₹55.49 lakhs. The company also reported its new Logistics Services segment (via subsidiary Eikovivify Logistics), which contributed ₹141.93 lakhs to Q2 consolidated revenue.
Strong consolidated bottom-line growth driven by the new logistics subsidiary and healthy margin expansion, but the decline in standalone H1 revenue is a watch point; the company has also sharply reduced borrowings (standalone debt is now nil) and holds ₹761.69 lakhs in cash, suggesting an improving balance sheet.